Regulation - Ipsen

Filter

Current filters:

Ipsen

Popular Filters

Ipsen’s Dysport accepted for review by US FDA

Ipsen’s Dysport accepted for review by US FDA

28-11-2014

French drugmaker Ipsen says that the US Food and Drug Administration has accepted for review its supplemental…

DysportIpsenNeurologicalPharmaceuticalRegulationUSA

Ipsen receives priority review for sNDA for Somatuline

Ipsen receives priority review for sNDA for Somatuline

01-09-2014

French drugmaker Ipsen has received priority review for its supplemental New Drug Application from the…

Gastroenteropancreatic neuroendocrine tumorsIpsenOncologyPharmaceuticalRegulationSomatulineUS Food and Drug AdministrationUSA

Ipsen files sNDA for Somatuline for GEP-NETs

Ipsen files sNDA for Somatuline for GEP-NETs

01-07-2014

French drugmaker Ipsen has submitted a Supplemental New Drug Application to the US Food and Drug Administration…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Launch of Ipsen/Braintree's Eziclen/Izinova in Europe expected by end 2013

07-02-2013

French drugmaker Ipsen (Euronext: IPN) and US partner Braintree Laboratories yesterday announced today…

Braintree LaboratoriesEuropeEziclenGastro-intestinalsIpsenIzinovaPharmaceuticalRegulation

US FDA puts clinical hold on Ipsen and Inspiration's hemophilia drug candidate

11-07-2012

There was bad news for French drugmaker Ipsen (Euronext: IPN) and partner privately-held US firm Inspiration…

IB1001Inspiration BiopharmaceuticalsIpsenNorth AmericaPharmaceuticalRegulationResearch

Teijin and Ipsen's Somatuline cleared in Japan

01-07-2012

Japanese drugmaker Teijin Pharma (TYO: 3402) revealed last Friday that it has received manufacturing…

Asia-PacificIpsenPharmaceuticalRare diseasesRegulationSomatulineTeijin

Back to top